These data demonstrate that idelalisib is able to inhibit AKT phosphorylation induced by EC and VLA-4-triggering, indicating that idelalisib interferes with CLL cell adhesion by inhibition of VLA-4 integrin function and signaling. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.